Drug Enforcement D-0286-2025

Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.

Status

Ongoing

Classification

Class II

Report Date

March 26, 2025

Termination Date

Product Information

Product description
Neupogen (filgrastim) For Injection, 480 mcg/1.6 mL (300 mcg/1 mL), 1.6 mL single Dose Vial, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solution - No Preservative, Amgen Inc. Thousand Oaks, CA 91320, NDC 55513-546-01 (vial), NDC 55513-546-10 (box).
Product quantity
258,750 Vials
Reason for recall
Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.
Recall initiation reason
Initial firm notification
Letter
Distribution pattern
Nationwide in the U.S.A. and Belgium/Luxembourg, Brazil, Chile, Colombia, France/French Guiana, Germany, Ireland, Italy/San Marino, Netherlands, Poland, Spain/Andorra, Sweden, Finland, Switzerland/Liechtenstein, United Kingdom of Great Britain and Northern Ireland, Ireland, Denmark, Canada, Hong Kong, Philippines, Israel, Malaysia, Saudi Arabia, Gibraltar.

Location & Firm

Recalling firm
Amgen, Inc.
Address
1 Amgen Center Dr, N/A

United States
Voluntary / Mandated
Voluntary: Firm initiated
Status date

Codes & Dates

Recall number
D-0286-2025
Event ID
96325
Recall initiation date
February 27, 2025
Center classification date
March 18, 2025
Code info
Lot 1147308, 1154183, Exp.: 2/28/2025; 1156807, 1160222, Exp.: 6/30/2025; 1160223, 1163912, 1167352, Exp.: 2/28/2026; 1171365, 1175057, 1176250, Exp.: 11/30/2026.
More code info